Viteva  Home logo
Supplement Safety

 Untitled 1
Niacin Research

Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.

Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients.

Present-day uses of niacin: effects on lipid and non-lipid parameters.

Nicotinic acid in the treatment of hyperlipidaemia.

Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?

Effects of niacin on glucose control in patients with dyslipidemia.

Nicotinic acid: recent developments.

Niacin use and cutaneous flushing: mechanisms and strategies for prevention.

The safety of niacin in the US Food and Drug Administration adverse event reporting database.

Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.

Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.

Niacin for stroke prevention: evidence and rationale.

Does nicotinic acid (niacin) lower blood pressure?

Niacin: an old drug rejuvenated.

Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance.

Nicotinic acid: a new look at an old drug.

Niacin status and treatment-related leukemogenesis.

Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome.

Nicotinic acid and the prevention of coronary artery disease.

Extended-release niacin (nicotinic acid)/laropiprant.

The vitamin nicotinamide: translating nutrition into clinical care.
 Untitled 1
   Home    Terms of Use    Privacy
Home    Research    Terms of Use    Privacy Policy    Advertise    Newsletter    About Us    Contact Us
Copyright ©2009 Viteva